Efungumab
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.
As such, it "grabs" onto fungal hsp90, hence its proposed trade name. Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.
Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. Chemically, efungumab is a single-chain variable fragment of a human monoclonal antibody.
As such, it "grabs" onto fungal hsp90, hence its proposed trade name. Its ability to potentiate the effects of the antifungal amphotericin B in culture were later found to be non-specific.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1346814656 under CC BY-SA 4.0; modifications have been made.